scholarly journals Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium

2013 ◽  
Vol 166 (1) ◽  
pp. 246-248 ◽  
Author(s):  
Beamon Agarwal ◽  
Matthew J. Campen ◽  
Meghan M. Channell ◽  
Sarah J. Wherry ◽  
Behzad Varamini ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Trial ◽  
Primary Prevention ◽  
Vascular Endothelium ◽  
Clinical Trial Evidence ◽  
Prevention Of Atherosclerosis ◽  
Trial Evidence

scholarly journals Sulfonylureas at the Glomerular Battlefield

2018 ◽  
Vol 14 (2) ◽  
pp. 15
Author(s):  
Sanjay Kalra ◽  
Deepak Khandelwal ◽  
Sarita Bajaj ◽  
Ashok Kumar Das
Keyword(s):  
Clinical Trial ◽  
Glucose Homeostasis ◽  
Diabetes Complications ◽  
Cardiovascular Health ◽  
Glucose Lowering ◽  
Meeting Point ◽  
Normal Glucose ◽  
Clinical Trial Evidence ◽  
Trial Evidence

The kidney is important in the context of diabetes not only because it is involved in normal glucose homeostasis, but also because it is one of the most important end organs to be involved in diabetes complications. Glomeruli are the meeting point of both microvascular, or renal; and macrovascular, or cardiovascular, health in diabetes. Sulfonylureas are effective glucose-lowering drugs. While a sulfonylurea-based glucose-lowering strategy is nephro-safe and nephro-protective, this aspect of sulfonylurea pharmaco-biology has not been highlighted earlier. In this editorial, we discuss current preclinical and clinical trial evidence regarding the performance of modern sulfonylureas at the glomerular battlefield.

Sign in / Sign up

Export Citation Format

Share Document